Journal
VACCINE
Volume 32, Issue 19, Pages 2135-2138Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2014.02.055
Keywords
Malaria; Vaccines; Whole-parasite immunization; PfGAP; ISI
Categories
Funding
- National Institute of Allergy and Infectious Diseases [U19 AI08998601]
- National Institutes of Health [W81XWH-11-2-0184]
- U.S. Department of Defense and a Ruth L. Kirschstein National Research Service [F32 AI091129]
Ask authors/readers for more resources
Whole-parasite malaria vaccines have shown promise in clinical trials. We recently reported the first human trial of a malaria vaccine based on Plasmodium falciparum genetically attenuated parasites (PfGAP). Herein we report for the first time that PfGAP induces prolonged functional humoral responses in humans. Six volunteers were exposed to 5 bites of PfGAP-infected mosquitoes followed by approximately 200 bites. Plasma collected from all volunteers 3 months after the last exposure efficiently inhibits invasion of hepatocytes by P. falciparum sporozoites. The level of inhibition observed is comparable to that attained using plasma collected after 4-5 intravenously administrations of high numbers of irradiated sporozoites, validating the potential of PfGAP malaria vaccines. Our data highlight the role of antibody responses in pre-erythrocytic stages of human malaria, and suggests that to be protective, malaria vaccines might need to elicit long-lasting functional antibodies in addition to cellular responses. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available